The use of P2X7 targeted small molecule inhibitors and P2RX7 genetic knock out in a murine melanoma model leads to modulation of CD39 and CD73 expression levels on several immune cell populations including Tregs, CD4+ effector lymphocytes, macrophage and DCs (De Marchi et al., 2019). The gene discussed is P2RX7; the disease is melanoma.